# Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

> **NCT00002174** · NA · COMPLETED · sponsor: **Louisiana State University Health Sciences Center in New Orleans** · enrollment: 20 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00002174
- **Lead sponsor:** Louisiana State University Health Sciences Center in New Orleans
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 20 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002174, "Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00002174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*